China In-Licensing Model Still Has Profitable Legs: LianBio CEO

China- and US-based biotech LianBio is advancing three late-stage clinical assets in hopes that successful commercialization could lead to profitability and validate its in-licensing business model in a challenging environment.

sales ramp-up — LianBio girds loins for plunge into Asian hypertrophic cardiomyopathy market • Source: Shutterstock

Despite ongoing headwinds from cool investor sentiment, the business model of in-licensing assets from foreign drug makers still holds appeal in China, Yizhe Wang, CEO of Nasdaq-listed LianBio, tells Scrip.

Founded in 2019 and based on this model, which would soon be proven by Zai Lab Ltd.'s successful introduction...